Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics is a medical technology company focused on the development and commercialization of a non-surgical, non-invasive, and low-cost treatment for sleep-disordered breathing. The company's revenue grew by 16% in 2025, and management expects revenue growth to continue in 2026 as operational efficiency improves. However, share dilution may be inevitable as the company requires additional capital to fund operations and service its debt. The company's Q4 results were choppy due to its transition from a legacy VIP/dentist model to a sleep-center model, resulting in a decline in product sales. To reflect the higher share count, our 12-month price target is lowered to $2.50 per share. However, risks to achieving this target include lower-than-projected sales growth and the need for additional financing.

Vivos Therapeutics is currently facing a number of challenges that may negatively impact its stock. The company's recent increase in gross margins is a positive trend, but the uncertainty of what a steady-state margin will be and its need for additional capital infusion in the near future are concerning. Additionally, the company's transition to a new distribution strategy and the consolidation of its sleep center operations have resulted in increased net losses, adding to the company's financial risks. Furthermore, while Vivos offers a promising alternative to the current standard of care for sleep-disordered breathing, the company's success will depend on its ability to successfully develop its channel and offerings.